Chief Operating Officer · Damora Therapeutics, Inc. (DMRA)

Anders Pedersen

A named executive officer of Damora Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,502,051

Salary $420,055Stock awards $0Bonus $120,340

FY2020: $1,091,173

3rd of 3 named executive officers at Damora Therapeutics by FY2021 total.

3 named officers on file for Damora Therapeutics, FY2021

Anders Pedersen’s pay file — $29

  • 3 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Damora Therapeutics’s whole pay program stands against its peers

  • Damora Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DMRA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Anders Pedersen’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anders Pedersen compensation by year

Damora Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Damora Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021
Salary$270,000$292,136$420,055
Bonus$85,000$157,523$120,340
Stock awards$0$0$0
Option awards$0$641,514$961,656
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$0$0$0
Total$355,000$1,091,173$1,502,051

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Damora Therapeutics, Inc. DEF 14A filed April 28, 2022, accession 0000950170-22-006557, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Damora Therapeutics, Inc. filed document, accession 0000950170-22-006557. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

$355K
$1.1M
$1.5M
FY19
FY20
FY21
SalaryBonusOption awards

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option29,788—$1.95
Option53,620—$7.70
Option100,000—$13.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Damora Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2021 proxy (filed April 28, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-01-04Grant or award derivative—115,000$0.00115,000

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Damora Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Hans SchambyePresident and Chief Executive Officer$2,947,004
Jonathan FreveChief Financial Officer$1,514,891
Anders Pedersen · this pageChief Operating Officer$1,502,051

The full Damora Therapeutics compensation record

free company brief

This page is one person within Damora Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Damora Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anders Pedersen's compensation dossier · One-time report. No refunds.